Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. Back in 2019 ...

It was found that NAD or the nicotinamide adenine dinucleotide is the fuel for the cellular engines which is necessary for the proper functioning of the body. However, an enzyme called CD38 breaks ...

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...